மேற்கோள் அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from மேற்கோள் அறிவியல். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In மேற்கோள் அறிவியல் Today - Breaking & Trending Today

Inhalable Drugs Market Trends and Vendors Analysis after Covid-19 Pandemic Opportunities Scenario Highlighting Major Drivers & Trends 2021-2028 – KSU


Inhalable Drugs Market
5
Global Inhalable Drugs Market, By Product Type (Aerosol, Dry Powder Formulation, Spray), Application (Respiratory Diseases, Non-Respiratory Diseases), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Inhalable drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 38.32 billion by 2028 and will grow at a CAGR of 5.65% in the above mentioned forecast period. ....

United States , Hong Kong , United Kingdom , South Africa , Saudi Arabia , South Korea , Avalyn Pharma , Glaxosmithkline Plc , Pharmaxis Ltd , Technology Penetration , Nelson Laboratories , Merck Co Inc , Quotient Sciences , Boehringer Ingelheim International Gmb , Effrx Pharmaceuticals , Cipla Inc , Intertek Group , Vectura Group , Market Research , Catalent Inc , Teicos Pharma Ltd , Mundipharma International , Global Inhalable Drugs Market , Product Type , Dry Powder Formulation , Respiratory Diseases ,

Nanoform 1-12/2020 report and new company near-term target introduced


Nanoform 1-12/2020 report and new company near-term target introduced
Nanoform
Company Announcement
Nanoform 1-12/2020 report and new company near-term target introduced
First GMP manufacturing campaign and first dosing in humans successfully completed, positive interim results from first clinical study announced, all near-term business targets set out in IPO achieved, ten new Small Molecule PoC projects started, four more non-GMP lines commissioned, first Biologics PoC project commenced and a new near-term business target introduced: “At least 3 new non-GMP lines in 2021 and 2 new GMP lines in 2022”.
10-12/2020 key financials:
- Revenue was EUR 186 thousand (EUR 49 thousand in 10-12/2019).
- The gross profit and margin came in at EUR 135 thousand and 73%, during 10-12/2019 the gross profit was negative. ....

Eteläuomen Läi , United States , United Kingdom , April Nanoform , Johanna Tuomisto , Eric Peter , Miguel Calado , July Nanoform , Biologics Po , Sergie Letser , Christian Jones , Cynthia Schwalm , June Nanoform , Finnish Financial Supervisory Authority , Finnish Medicines Agency , Finland Branch , Orion Corporation , Nanoform United States Inc , Danske Bank , Coast Us Biotech Company , Nanoform Finland Plc , Herantis Pharma Plc , Company Announcement , Small Molecule Poc , Biologics Poc , January Nanoform United States ,